<DOC>
	<DOC>NCT03093649</DOC>
	<brief_summary>Although patient-reported adverse events have been promoted as an essential element in clinical trials and daily managements, their efficacy remained unknown. The purpose of this trial was to determine the effect of the patient-reported adverse events during the treatment on the improvements on quality of life.</brief_summary>
	<brief_title>Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<criteria>Patients with newly histologically confirmed nonkeratinizing carcinoma (according to WHO histological type) No evidence of distant metastasis (M0) Performance status: PS 0~2 Receive standard treatment Able to read and understand the questionnaires Not exhibiting overt psychopathology Willing to give feedback to physicians and written informed consent was obtained WHO type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma. Treatment with palliative intent. Prior malignancy (except adequately treated carcinoma insitu of the cervix or basal/squamous cell carcinoma of the skin) Previous chemotherapy or radiotherapy (except nonmelanomatous skin cancers outside the intended RT treatment volume) Patient is pregnant or lactating Severe intercurrent disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>